Third Line TKI After 2 TKIs in Patients With mRCC (Tokio Study)

NCT03456401 · clinicaltrials.gov ↗
PHASE2
Phase
TERMINATED
Status
18
Enrollment
OTHER
Sponsor class

Stopped availability of new and more promising therapeutic agents than expected in the experimentation in question

Conditions

Interventions

Sponsor

Fondazione IRCCS Istituto Nazionale dei Tumori, Milano